key: cord-0696337-027twgah authors: Tripathi, Raghav; Archibald, Laura K.; Mazmudar, Rishabh S.; Conic, Rosalynn RZ.; Rothermel, Luke D.; Scott, Jeffrey F.; Bordeaux, Jeremy S. title: Racial Differences in Time to Treatment for Melanoma date: 2020-04-08 journal: J Am Acad Dermatol DOI: 10.1016/j.jaad.2020.03.094 sha: 3028e5ac8d6858dd81cf20fae61fbe38a4dc5e37 doc_id: 696337 cord_uid: 027twgah Abstract Background Longer time from diagnosis to definitive surgery (TTDS) is associated with increased melanoma-specific mortality. Although Black patients present with later stage melanoma and have worse survival than non-Hispanic white (NHW) patients, the association between race and TTDS is unknown. Objective To investigate racial differences in time to melanoma treatment. Methods Retrospective review of the National Cancer Database (2004-2015). Multivariable logistic regression was used to evaluate the association of race with TTDS controlling for sociodemographic/disease characteristics. Results Of the 233,982 melanoma patients identified, 1,221 (0.52%) were Black. Black patients had longer TTDS for stage I-III melanoma (p<0.001) and time to immunotherapy (p=0.01), but not for TTDS for stage IV melanoma or time to chemotherapy (p>0.05 for both). Controlling for sociodemographic characteristics, Black patients had over twice the odds of having TTDS between 41-60 days, over three times the odds of having TTDS between 61-90 days, and over five times the odds of having TTDS over 90 days. Racial differences in TTDS persisted within each insurance type. Patients with Medicaid had the longest TTDS (mean 60.4 days), and those with private insurance had the shortest TTDS (mean 44.6 days; p<0.001 for both). Conclusions Targeted approaches to improve TTDS for Black patients are integral in reducing racial disparities in melanoma outcomes. An estimated 2.3% of Americans are diagnosed with cutaneous melanoma annually, and the national incidence of cutaneous melanoma has continued to rise over the past decade. 1 It has been shown that dermatology visits reduce adverse events, mortality, and unnecessary hospitalizations for melanoma patients. 2, 3 However, substantial disparities in access to and utilization of dermatologic care for melanoma patients have been demonstrated for a myriad of clinical and sociodemographic factors including age, sex, rurality, provider supply, distance to dermatologic care, and poverty rate. 4, 5 Specifically, race and insurance status are associated with differences in disease-specific mortality for melanoma patients. [6] [7] [8] Black patients present with later stage melanoma, and later stage melanoma at diagnosis and increased time to treatment for stage I melanoma have each independently been associated with increased melanoma-specific mortality. 6, [8] [9] [10] Despite this, the association between race and time from diagnosis to definitive surgery (TTDS) is unknown. As such, our primary goal was to investigate differences in TTDS between Black and non-Hispanic white (NHW) melanoma patients. Our secondary goals were to determine differences in TTDS between Black and NHW patients by melanoma stage and insurance type, and to examine racial differences in stage at presentation, distance from the hospital, and time to medical treatment (immunotherapy and chemotherapy). Patients with cutaneous melanoma were identified using the National Cancer Database Committee on Cancer (AJCC) pathologic stage I-IV cutaneous melanoma were included in this study. TTDS was calculated as the number of days between initial diagnosis and definitive surgical resection of the primary tumor. Patients with missing data for covariates, unknown stage, or excisional biopsy as definitive treatment (TTDS of zero days) were excluded. Descriptive analyses were performed for initial univariate comparison of sociodemographic characteristics between racial groups using Pearson's Chi-Square and analysis of variance (ANOVA). Student's t-test (pooled) was initially used for univariate comparison of time to immunotherapy and chemotherapy, as well as for TTDS stratified by stage and insurance type between racial groups. Multivariable logistic regression was used to evaluate the association of race with TTDS controlling for sex, age, median household income, and insurance type. In the multivariable model, adjusted odds ratios were calculated for Black patients (reference group: non-Hispanic white). Institutional Review Board approval was not required for the use of this publicly available, de-identified database. All analyses were performed in the statistical software R, and p<0.05 was considered significant. 11 Table 4 ). In this study, Black patients had greater TTDS for stages I-III melanoma and greater time to immunotherapy compared to NHW patients, and the racial differences in TTDS persisted within each insurance type. There were no racial differences in TTDS for Stage IV melanoma or time to chemotherapy. Additionally, compared to NHW patients, Black patients had over twice the odds of having TTDS between 41-60 days, over three times the odds of having TTDS between 61-90 days, and over five times the odds of having TTDS over 90 days. These findings add to the literature by demonstrating increased TTDS for Black patients with melanoma after controlling for sex, age, income, and insurance type. Our data suggest that increased TTDS in Black patients with melanoma may be an independent explanatory factor for racial differences in melanoma survival alongside factors such as later stage at presentation, biological differences in melanoma characteristics, and differences in healthcare utilization. 6, 9, 12 Multiple unfavorable socioeconomic factors may exacerbate overall health status more than the additive effects of each of the individual factors. 13 Racial differences in TTDS persisted within each insurance group, implying that insurance status does not fully account for racial TTDS disparities. We found that Black patients also had increased TTDS despite living closer to hospitals, suggesting physical distance from the hospital is not as much of a contributor to TTDS for melanoma as for other cancers (e.g. colorectal). 14 A recent study of three high-risk surgical procedures showed that Black patients lived closer to high-quality hospitals but were 25-58% more likely to receive surgery at low-quality hospitals than NHW patients; it is possible that a similar phenomenon exists in TTDS for melanoma. 15 The quality and availability of melanoma treatment may thus be significantly different between racial groups for reasons other than travel burden . 15 Abbreviations: TTDS, time to definitive surgical treatment; NHW, non-Hispanic white; SD, standard deviation. Abbreviations: TTDS, time to definitive surgical treatment; NHW, non-Hispanic white; SD, standard deviation. Abbreviations: CI, confidence interval. The Impact of Dermatology Consultation on Diagnostic Accuracy and Antibiotic Use Among Patients With Suspected Cellulitis Seen at Outpatient Internal Medicine Offices The influence of dermatologist and primary care physician visits on melanoma outcomes among Medicare beneficiaries Distance to diagnosing provider as a measure of access for patients with melanoma Dermatologic health disparities Racial disparities in melanoma survival Association of Delays in Surgery for Melanoma With Insurance Type Racial disparities and insurance status: an epidemiologic analysis of Ohio melanoma patients Determination of the impact of melanoma surgical timing on survival using the National Cancer Database Factors associated with time to surgery in melanoma: An analysis of the National Cancer Database R: A language and environment for statistical computing Association of demographic and socioeconomic characteristics with differences in use of outpatient dermatology services in the United States Racial and insurance status disparities in patient safety indicators among hospitalized patients Association between travel distance and metastatic disease at diagnosis among patients with colon cancer Black patients more likely than whites to undergo surgery at low-quality hospitals in segregated regions Malignant Melanoma in African-Americans A Population-Based Clinical Outcomes Study Involving 1106 African-American Patients from the Surveillance, Epidemiology, and End Result (SEER) Database Current Surgical Management of Diagnosis and Management of Acral Lentiginous Melanoma Comparison of secondary intention healing and full-thickness skin graft after excision of acral lentiginous melanoma on foot Prognosis of acral melanoma: a series of 281 patients Racial Disparities in Breast Cancer Survival: An Analysis by Age and Stage Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States Immunotherapy disparities in metastatic melanoma The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States Raghav Tripathi had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. There are no potential conflicts of interest. There are no relevant financial activities outside the submitted work. There are no relationships or activities that could influence or appear to potentially influence what is written in this work. There was no funding for this work.